Valley National Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Valley National Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,680	Closed	-$16K	–	1067
2026 Q1	$16K	Buy	4,680 +3,000	+179%	+$9.6K	﹤0.01%	532
2025 Q4	$4K	Buy	+1,680	New	+$3.89K	﹤0.01%	707
2022 Q1	–	Sell	-200	Closed	-$4K	–	950
2021 Q4	$4K	Hold	200	–	–	﹤0.01%	712
2021 Q3	$5K	Hold	200	–	–	﹤0.01%	658
2021 Q2	$5K	Buy	+200	New	+$5.2K	﹤0.01%	671

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Valley National Advisers's IOVA Position: Q2 2026 in Review

Valley National Advisers sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 4,680 shares — an estimated $16K sold.

Valley National Advisers first reported a position in IOVA in Q2 2021 and held it in 5 quarters. The position peaked at $16K in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Valley National Advisers reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Valley National Advisers sold 4,680 Iovance Biotherapeutics shares in Q2 2026, an estimated $16K.
Valley National Advisers first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 5 quarters.
Valley National Advisers's Iovance Biotherapeutics position peaked at $16K in Q1 2026.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.